NFKBIB Knockout cell line (BEAS-2B)

CRISPR knockout cell lines are engineered through targeted genome editing to eliminate gene function, supporting studies of cellular biology, disease mechanisms, and drug discovery.

NFKBIB (NFKB inhibitor beta) encodes an inhibitor of the NF-kappa-B signaling pathway that binds NF-kappa-B and retains it in the cytoplasm, preventing its transcriptional activity. Phosphorylation of NFKBIB promotes its ubiquitination and degradation, allowing NF-kappa-B to translocate to the nucleus and regulate gene expression. NFKBIB therefore contributes to the control of NF-kappa-B-dependent cellular signaling and transcriptional responses.

BEAS-2B is an immortalized human bronchial epithelial cell line established from normal bronchial epithelium obtained from non-cancerous individuals. The cells were immortalized using a replication-defective SV40/adenovirus 12 hybrid (Ad12SV40) and cloned. BEAS-2B cells express epithelial markers including keratins and SV40 T antigen and can undergo squamous differentiation in response to serum exposure. The cell line is widely used as a model for studying normal airway epithelial biology, respiratory infection mechanisms, epithelial differentiation, environmental toxicity, and carcinogenesis.

Each knockout cell line is validated by STR authentication, sterility testing (bacteria/fungi), and mycoplasma screening. Genotype is confirmed by two rounds of PCR and Sanger sequencing. Only clones that pass all QC criteria are released, ensuring reliable identity and performance for downstream applications.